Corrigendum to “Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study” [Vaccine: X 11 (2022) 100189]

Corrigendum to “Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study” [Vaccine: X 11 (2022) 100189]

Bibliographic Details
Main Authors:	Xavier Sáez-Llorens, Claudio Lanata, Elaine Aranguren, Carlos R. Celis, Rubelio Cornejo, Rodrigo DeAntonio, Lucie Ecker, Diegi Garrido, Ana I. Gil, Marina Gonzales, Morgan Hess-Holtz, Geert Leroux-Roels, Helga Junker, Sarah-Katharina Kays, Sven D. Koch, Sandra Lazzaro, Philipp Mann, Gianluca Quintini, Barkha Srivastava, Dominik Vahrenhorst, Philipp von Eisenhart-Rothe, Olaf-Oliver Wolz, Lidia Oostvogels
Format:	Article
Language:	English
Published:	Elsevier 2023-08-01
Series:	Vaccine: X
Online Access:	http://www.sciencedirect.com/science/article/pii/S2590136223000487

Similar Items

Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study
by: Xavier Sáez-Llorens, et al.
Published: (2022-08-01)

A Third Dose of the COVID-19 Vaccine, CVnCoV, Increased the Neutralizing Activity against the SARS-CoV-2 Wild-Type and Delta Variant
by: Olaf-Oliver Wolz, et al.
Published: (2022-03-01)

A third dose of the unmodified COVID-19 mRNA vaccine CVnCoV enhances quality and quantity of immune responses
by: Klara Lenart, et al.
Published: (2022-12-01)

mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents
by: Susanne Rauch, et al.
Published: (2021-04-01)

Immune response and reactogenicity after immunization with two-doses of an experimental COVID-19 vaccine (CVnCOV) followed by a third-fourth shot with a standard mRNA vaccine (BNT162b2): RescueVacs multicenter cohort study
by: Ana Ascaso-del-Rio, et al.
Published: (2022-09-01)

The mRNA-LNP vaccines – the good, the bad and the ugly?
by: Botond Z. Igyártó, et al.
Published: (2024-02-01)

Engineered EVs with pathogen proteins: promising vaccine alternatives to LNP-mRNA vaccines
by: Bin Zhang, et al.
Published: (2024-01-01)

CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2
by: Donata Hoffmann, et al.
Published: (2021-06-01)

Comparative immunogenicity of an mRNA/LNP and a DNA vaccine targeting HIV gag conserved elements in macaques
by: Antonio Valentin, et al.
Published: (2022-07-01)

Safety, Immunogenicity, and Mechanism of a Rotavirus mRNA-LNP Vaccine in Mice
by: Chenxing Lu, et al.
Published: (2024-01-01)

Period stability in AM CVn
by: Provencal J. L.
Published: (1995-09-01)

The secondary star in AM CVn
by: Nymark T. K., et al.
Published: (1995-09-01)

Modelling on CVN toughness of weld deposits
by: Chauhan, Rudrang, et al.
Published: (2022)

The AM CVn trial: the case for superhumps
by: O’Donoghue D.
Published: (1995-09-01)

The AM CVn type stars: an overview
by: Solheim J.-E.
Published: (1995-09-01)

Impact of Ribosome Activity on SARS-CoV-2 LNP – Based mRNA Vaccines
by: Evangelos Tsiambas, et al.
Published: (2021-04-01)

Correlating Stability-Indicating Biochemical and Biophysical Characteristics with In Vitro Cell Potency in mRNA LNP Vaccine
by: Xin Tong, et al.
Published: (2024-02-01)

Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability
by: Lizhou Zhang, et al.
Published: (2023-10-01)

Development and Characterization of an In Vitro Cell-Based Assay to Predict Potency of mRNA–LNP-Based Vaccines
by: Nisarg Patel, et al.
Published: (2023-07-01)

Modified mRNA-LNP Vaccines Confer Protection against Experimental DENV-2 Infection in Mice
by: Mengling Zhang, et al.
Published: (2020-09-01)

The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory
by: Sonia Ndeupen, et al.
Published: (2021-12-01)

Lipid Nanoparticle (LNP) Delivery Carrier-Assisted Targeted Controlled Release mRNA Vaccines in Tumor Immunity
by: Liusheng Wu, et al.
Published: (2024-02-01)

Validation of an HPLC-CAD Method for Determination of Lipid Content in LNP-Encapsulated COVID-19 mRNA Vaccines
by: Xiaojuan Yu, et al.
Published: (2023-05-01)

Development of an LNP-Encapsulated mRNA-RBD Vaccine against SARS-CoV-2 and Its Variants
by: Cong Liu, et al.
Published: (2022-05-01)

Reflexiones acerca de construcciones verbo-nominales/cvn
by: Gerd Wotjak
Published: (2006-01-01)

WASP light curve of the eclipsing binary VZ CVn
by: Latković O.
Published: (2012-01-01)

Potent and long-lasting humoral and cellular immunity against varicella zoster virus induced by mRNA-LNP vaccine
by: Anannya Bhattacharya, et al.
Published: (2024-04-01)

mRNA-LNP expressing PfCSP and Pfs25 vaccine candidates targeting infection and transmission of Plasmodium falciparum
by: Clifford T. H. Hayashi, et al.
Published: (2022-12-01)

1142 mRNA LNP vaccination with the tumor-specific antigen EGFRvIII bolsters CAR T cell activity in vivo
by: Tyler E Papp, et al.
Published: (2023-11-01)

Cataclysmic Variables with Evolved Secondaries and the Progenitors of AM CVn Stars
by: Podsiadlowski, P, et al.
Published: (2001)

Starspot Model of RS CVn Type Binary SZ PSC
by: Young Woon Kang
Published: (2000-12-01)

Element abundances in the ES CVn-type star Lambda Andromedae
by: Tautvaišiene G., et al.
Published: (1992-12-01)

Chemical Composition of the RS CVN-Type Star 29 Draconis
by: Barisevičius G., et al.
Published: (2010-12-01)

Chemical Composition of the RS CVn-Type Star Lambda Andromedae
by: Tautvaišienė G., et al.
Published: (2010-06-01)

Chemical composition of a halo carbon star TT CVn.
by: Kipper T.
Published: (1992-06-01)

mRNA-LNP vaccination-based immunotherapy augments CD8+ T cell responses against HPV-positive oropharyngeal cancer
by: Ke Qiu, et al.
Published: (2023-09-01)

Development of an mRNA-LNP Vaccine against SARS-CoV-2: Evaluation of Immune Response in Mouse and Rhesus Macaque
by: Alireza Naderi Sohi, et al.
Published: (2021-09-01)

Development of Lipid Nanoparticles [LNP]-RNA Vaccine Against Neisseria Meningitidis CPS Gene Locus Facilitating the Synthesis of The Capsular Polysaccharide in Egypt
by: Mohammed Kassab
Published: (2023-02-01)

Analysing the In-Use Stability of mRNA-LNP COVID-19 Vaccines Comirnaty™ (Pfizer) and Spikevax™ (Moderna): A Comparative Study of the Particulate
by: Jesús Hermosilla, et al.
Published: (2023-10-01)

Author Correction: mRNA-LNP expressing PfCSP and Pfs25 vaccine candidates targeting infection and transmission of Plasmodium falciparum
by: Clifford T. H. Hayashi, et al.
Published: (2023-08-01)